Status: Not yet recruiting
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function alterations and/or other defects in the DNA damage repair (DDR) pathway.
Participants needed: 112
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Danatlas Pharmaceuticals Co., LtdUpdated: Sep 27, 2024Locations: 2
Eligibility criteria
Signed informed consent prior to initiation of any procedures in this study. [+9]
Patients who received systemic chemotherapy, small-molecule targeted drugs withi... [+17]